Health TrialsbyHealthPanel

A Study of CS060380 Tablets in Patients With MASH and Obesity

ConditionsMetabolic Dysfunction-associated Steatohepatitis (MASH)Obesity
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCascade Pharmaceuticals, Inc

About this trial

this study is looking at a new investigational medicine called CS060380, when used together with semaglutide, in adults who have both metabolic dysfunction-associated steatohepatitis (MASH) and obesity. MASH is a condition where too much fat builds up in the liver, leading to inflammation and damage. Obesity is a major risk factor for this condition.

This is a Phase II clinical trial, which means we are testing the medicine to see if it works and is safe. The study will last up to 54 weeks, which is a little over a year. It includes:

* A screening period of up to 2 weeks to check if you are eligible to take part. * A 36-week double-blind treatment period, where you will be randomly assigned (like flipping a coin) to receive either the study drug CS060380 or a placebo (an inactive pill that looks like the study drug). Both groups will also receive semaglutide, which is an approved medicine for weight management. Neither you nor your doctor will know which treatment you are receiving. * A 16-week open-label period, where all participants will receive CS060380. The main goal of this study is to see how the study drug affects the amount of fat in the liver, measured by a special MRI scan, and body weight. We will also monitor your overall health and safety throughout the study by checking your vital signs, doing blood and urine tests, and asking about any side effects you might experience.

About 120 participants will take part in this study at almost 15 different hospitals across China, with Ruijin Hospital in Shanghai as the main study site.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 65 years (inclusive), male or female.

Liver fat content ≥10% as measured by MRI-PDFF at screening.

BMI ≥30 kg/m².

Body weight change ≤5% during the 3 months prior to screening with only diet and exercise control (self-reported). The weight change is calculated as: (Maximum weight - Minimum weight within 3 months before screening) / Maximum weight × 100%.

Disqualifiers

≥2 episodes of hypoglycemia (blood glucose ≤2.8 mmol/L in non-diabetic patients) within 6 months before screening.

Impaired gastrointestinal function or gastrointestinal disease that may affect the absorption of oral medications, such as severe gastrointestinal diseases (peptic ulcer, erosive or atrophic gastritis), partial gastrectomy, or grade >1 gastrointestinal symptoms (e.g., nausea, vomiting, or diarrhea) at screening.

Thyroid diseases including hyperthyroidism and hypothyroidism [participants with benign thyroid lesions (e.g., thyroid nodules) may participate in this study] or pituitary diseases, or long-term use of thyroid hormone replacement therapy, antithyroid drugs, or drugs that may affect thyroid hormone production and/or interfere with thyroid function (including but not limited to methimazole, propylthiouracil, tyrosine kinase inhibitors, lithium, iodides, and glucocorticoids, etc.).

Previous diagnosis of obesity caused by endocrine diseases or single-gene mutations, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, and hypogonadism.

Trial design

Design model

Parallel

Treatments tested in this trial

  • semaglutide

    Drug

    Semaglutide 1.7 mg as the background therapy for all participants

  • CS060380

    Drug

    CS060380 1.0 mg tablets for the treatment of metabolic dysfunction-associated steatohepatitis complicated with obesity

  • Placebo

    Drug

    Placebo tablets matching CS060380 of double-blind control for 36 weeks

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Placebo + SemaglutidePlacebo comparator 2 interventions
Group B: CS060380 1.0 mg + SemaglutideExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF)

Percentage change in liver fat content measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) from baseline to Week 36 of the double-blind treatment period.

Time frame
Baseline, Week 36

Secondary outcomes

1

Percentage change in body weight measured by weight scale from baseline to Week 36

Percentage change in body weight from baseline to Week 36, measured using a weight scale

Time frame
Baseline, Week 36
2

Percentage change in liver fat content (MRI-PDFF) from baseline to week 24

Percentage change in liver fat content as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) from baseline to Week 24

Time frame
Baseline, Weeks 24

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cascade Pharmaceuticals, Inc

Lead sponsor

Source ClinicalTrials.gov
Apply now